SANOFI-EFC6521



A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy
Semuloparin
EFC6521
NCT00694382
Thromboprophylaxis
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria.
November 2015